About TRAD CHI MED Company

China National Chinese Medicine Holdings Limited ("China National Chinese Medicine") is the core platform of the Chinese medicine industry within China National Pharmaceutical Group Corporation ("Sinopharm"). The company is listed on the Main Board of the Hong Kong Stock Exchange as a red-chip entity (stock code: 00570.HK), with its headquarters and management center located in Foshan, Guangdong. It employs approximately 18,000 people and operates more than 100 subsidiaries. The company boasts a comprehensive industrial chain integrating research, manufacturing, and sales. It offers over 800 finished‑product specifications—more than 280 of which were included in the 2018 edition of the National Essential Medicines List—alongside over 700 single‑herb traditional Chinese medicine granule varieties and more than 400 classic compound concentrated granules exclusively for export. Its operations span the entire value chain, from the cultivation and harvesting of medicinal herbs to processed herbal slices, formula granules, proprietary Chinese medicines, and broader health‑related products. Drawing on the essence of traditional Chinese medicine and spanning over 400 years of history, China National Chinese Medicine carries forward time‑honored brands such as "Liang Zhonghong Wax Pill Workshop," "Feng Liaoxing," "Tongjitang," and "Yuan Jilin." The company holds three Chinese Timeless Brands—"Feng Liaoxing," "Anning," and "Tongjitang"—five well‑known trademarks—"Xianling," "Tongjitang," "Xianling Gubao," "Tianjiang Pharmaceutical," and "Dezhong"—four items of intangible cultural heritage—"Tongjitang Traditional Chinese Medicine Culture," "Feng Liaoxing Rheumatism and Trauma Medicinal Wine," "Shaolin Trauma Pain Relief Ointment," and "Yuan Jilin Sweet and Herbal Tea"—as well as ten nationally exclusive essential medicines: "Xianling Gubao Capsules," "Jingshu Granules," "Rheumatic Bone Pain Capsules," "Qili Capsules," "Runzao Anti‑Itch Capsules," "Zaoren Anshen Capsules," "Yu Pingfeng Granules," "Biyan Kang Tablets," "Jinye Baidu Granules," and "Biejia Jian Pills." Committed to quality as its cornerstone, China National Chinese Medicine possesses premium brands and product portfolios that enjoy the trust of physicians and patients alike. Guided by the mission of "implementing the national strategy for developing traditional Chinese medicine and leading high‑quality growth in the Chinese medicine sector," the company will prioritize industrial development, leverage technological innovation, vigorously expand the medicinal resource industry, capitalize on its traditional trade strengths, and actively enter the realm of value‑added services in the greater health field. By sharing its multi‑billion‑dollar Chinese medicine platform with all stakeholders, it aims to become a leader in the Chinese medicine industry. On December 25, 2018, an announcement stated that Wang Xiaochun had assumed the role of President. On September 10, 2021, it was announced that Wang Xiaochun had been relieved of his presidential duties. On May 23, 2022, an announcement indicated that Chen Yinglong had been appointed Chairman of the Board. On March 26, 2024, an announcement confirmed that Chen Yinglong would serve as acting President.